Skip to main content
Premium Trial:

Request an Annual Quote

Alberto Mas, Patrick Kaltenbach, Bill Tozzi

Becton Dickinson has announced three executive leadership changes. Alberto Mas will now lead the firm's medical segment; Patrick Kaltenbach will head up life sciences, replacing Mas, effective May 29; and Bill Tozzi will lead the firm's interventional segment on an interim basis.

Mas was head of BD's life sciences business for two years, and previously served as president of three of the firm's other major business units. Kaltenbach previously served as senior vice president of life sciences and applied markets at Agilent. Tozzi had been serving as the integration leader for the CR Bard transaction since April 2017, and prior to that was the president of the firm's medication delivery solutions division for six years. Tozzi will replace John Groetelaars, who served as the president of the interventional segment since the completion of the Bard transaction and who has decided to leave BD for an executive position at another company.

Mas was head of Life Sciences for two years, and previously served as president of three of the firms other major business units. 

Kaltenbach will replace Mas effective May 29, 2018. He previously served as senior vice president of life sciences and applied markets at Agilent, a position he held since 2014.

Tozzi had been serving as the integration leader for the CR Bard transaction since April 2017, and prior to that was the president of the firm's medication delivery solutions division for six years. Tozzi will replace John Groetelaars, who served as the president of the interventional segment since the completion of the Bard transaction and who has decided to leave BD for an executive position at another company.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.